{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.1","value":"1940"},{"groupId":"OG001","spread":"43.2","value":"2740"},{"groupId":"OG002","spread":"71.9","value":"3610"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fasted state","dispersionType":"Standard Deviation","groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA,TGB,TGC, and Part 2 TGA","id":"OG000","title":"8mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA,TGB, and Part 2 TGA","id":"OG001","title":"12mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA","id":"OG002","title":"16mg QD INCB057643"}],"paramType":"MEAN","populationDescription":"PK evaluable population includes all subjects who received at least 1 dose of study drug and had at least 1 PK sample collected and analyzed","reportingStatus":"POSTED","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8","title":"AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy","type":"SECONDARY","unitOfMeasure":"h*nM"}